Codexis Announces Inducement Option Award and Restricted Stock Award to John J. Nicols
REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Codexis, Inc. (CDXS), a developer of industrial enzymes to enable the cost-advantaged production of biofuels, bio-based chemicals and pharmaceutical intermediates, today announced that it has granted a stock option award and restricted stock award to John J. Nicols, Codexis newly appointed President and Chief Executive Officer. These inducement awards were approved by the Compensation Committee of the Codexis Board of Directors on June 12, 2012, effective as of June 13, 2012, and granted as an inducement material to Mr. Nicols entering into employment with Codexis in accordance with NASDAQ Listing Rule 5635(c)(4).
Codexis granted Mr. Nicols an option to purchase 400,000 shares of Codexis common stock with an exercise price equal to $3.46 per share, the closing price per share of common stock as reported by NASDAQ on June 13, 2012. The option will vest on June 13, 2013 as to 25 percent of the shares subject thereto, with the remaining shares vesting ratably on a monthly basis over a period of 36 months thereafter, subject to Mr. Nicols continuous service with Codexis through the applicable vesting date, such that the option would be fully vested and exercisable on June 13, 2016. In addition, Codexis granted to Mr. Nicols an award of 750,000 shares of restricted stock that will vest as to 25 percent of the shares subject thereto on each anniversary of June 13, 2012, subject to Mr. Nicols continuous service to Codexis through the applicable vesting date, such that the restricted stock ward will be fully vested on June 13, 2016, subject to accelerated vesting in accordance with Mr. Nicols employment agreement.
Codexis is providing this information in accordance with NASDAQ Listing Rule 5635(c)(4).
About Codexis, Inc.
Codexis, Inc. is a developer of industrial enzymes to enable the cost-advantaged production of biofuels, bio-based chemicals and pharmaceutical intermediates. Codexis' product lines include CodeXyme" Cellulase Enzymes and CodeXol" Detergent Alcohol. Partners and customers include global leaders such as Shell, Merck and Pfizer. For more information, see www.codexis.com.
Jay Sarwar, 650-421-8126 (Investors)
Wes Bolsen, 650-421-2356 (Media)
Source: Codexis, Inc.Copyright Business Wire 2012